Page 35 - Oncology Coder News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncology coder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncology Coder Today - Breaking & Trending Today

NeoGenomics Stock Plunges After Patent Infringement Ruling In Favor Of Natera

Shares of oncology testing services company, NeoGenomics, Inc. (NEO) stock tumbled 16.49% after Natera won preliminary Injunction in patent infringement suit against NeoGenomics' RaDaR Test. ....

Israel General , World Health Organization , Labor Department On , Health Organization , Labor Department , Patent Infringement ,

Beloit oncologist Dr. Walter Vogel to retire

Dr. Walter Vogel will retire at the end of this month after caring for cancer patients in Beloit for 36 years. ....

Walter Vogel , Cancer Care Center , Cancer Care Center , Beloit Health System , R Walter Vogel ,

Screenings, early detection important in prostate cancer treatment

It’s a mention in a newscast, a headline in a newspaper, an entry on a prayer list, and then, perhaps, forgotten. Except by the sufferer and his family. ....

United States , Hasan Rizvi , Bob Casey , Natalie Adams , Glenn Thompson , Roswell Park Cancer Institute ,

Family caregivers of patients with advanced cancer show variations in spiritual coping levels

1. In this cross-sectional study, family caregivers of patients with advanced cancer had moderate spiritual coping levels. 2. However, there were variations in spiritual coping levels based on demographic factors, such as gender, religious identity, and the presence of depression and anxiety. Evidence Rating Level: 3 (Average) Family caregivers of patients with advanced cancer provide ....

Spiritual Health Scale , Rating Level , Spiritual Coping Scale , Perceived Social Support Scale , Depression Scale , Spiritual Health Scale Short , Advanced Cancer , Religious Activity ,

Atezolizumab With Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer

1. Progression-free survival was 4.1 months in the combination arm vs 2.2 months in the monotherapy arm with an HR of 0.66. 2. Grade 3/4 serious adverse events occurred in 41% in the combination arm vs 8% in the monotherapy arm. Evidence Rating Level: 1 (Excellent) Study Rundown: Previous studies explored treating PD-L1–positive metastatic triple-negative ....

Rating Level , Metastatic Breast Cancer , Triple Negative Breast Cancer , Chronic Disease ,